Emcure Pharmaceuticals IPO

Emcure Pharmaceuticals Ltd.

Emcure Pharmaceuticals IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
To be announced------
Issue SizeIPO Doc
NA
DRHP PDF

About Emcure Pharmaceuticals

Emcure Pharmaceutical is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is the largest pharmaceutical company in India in the gynecology, blood-related, and HIV antivirals therapeutic areas, based on sales in India in the Financial Year 2021. Emcure is an R&D-driven company with a differentiated product portfolio that includes orals, injectables, and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine that has enabled it to reach a range of target markets across over 70 countries. ;
Parent Organisation
Emcure Pharmaceuticals Ltd.
Founded
1981
Managing Director
Satish Mehta

Strengths & Risks

  • Emcure’s core strength lies in its ability to research, develop, and manufacture in-house niche pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry.
  • Well-positioned to leverage leading position in the domestic market.
  • Large, diversified, and fast-growing product portfolio in the international markets.
  • Strong capabilities and a proven track record in building brands.
  • Extensive and diversified manufacturing capacity.
  • De-risked business model with a diversified income base.
  • Highly qualified, experienced, and entrepreneurial management team and board.
  • Business model focused on the compliance of Environmental, Social, and Governance (ESG) norms.
  • Any manufacturing or quality control problems.
  • Any delay, interruption, or reduction in the supply or transportation of its raw materials or finished products.
  • Slowdown or shutdown in its manufacturing or R&D operations.
  • Adverse order, including the imposition of penalties, in an investigation instituted by the Competition Commission of India against Emcure and others, alleging cartelization in the marketing of an oral anti-diabetes formulation.
  • Failure to obtain, maintain or renew its statutory and regulatory licenses, permits, and approvals required to operate its business.
  • Inability to accurately forecast demand for its products and manage its inventory.
  • Pricing pressure from customers may affect its ability to maintain or increase its product prices.
  • Significant proportion of its revenue is derived from its sale of products in certain therapeutic areas in India, such as the gynecology and cardiovascular therapeutic areas.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 3.6.9
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

ABOUT GROWW